Invention Application
WO2012053787A3 ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
审中-公开
具有HIF-1抑制活性的芳氧基苯氧基丙烯酸化合物，其制备方法以及含有该化合物作为活性成分的药物组合物
- Patent Title: ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
- Patent Title (中): 具有HIF-1抑制活性的芳氧基苯氧基丙烯酸化合物，其制备方法以及含有该化合物作为活性成分的药物组合物
-
Application No.: PCT/KR2011007710Application Date: 2011-10-17
-
Publication No.: WO2012053787A3Publication Date: 2012-07-26
- Inventor: LEE KYEONG , WON MI SUN , KIM HWAN MOOK , PARK SONG KYU , LEE KIHO , LEE KI HOON , LEE CHANG WOO , LEE JUNG JOON , CHUNG KYUNG SOOK , KIM BO KYUNG , JIN YINGLAN , LEE SEUNG-HEE
- Applicant: KOREA RES INST OF BIOSCIENCE , UNIV DONGGUK IND ACAD COOP , LEE KYEONG , WON MI SUN , KIM HWAN MOOK , PARK SONG KYU , LEE KIHO , LEE KI HOON , LEE CHANG WOO , LEE JUNG JOON , CHUNG KYUNG SOOK , KIM BO KYUNG , JIN YINGLAN , LEE SEUNG-HEE
- Assignee: KOREA RES INST OF BIOSCIENCE,UNIV DONGGUK IND ACAD COOP,LEE KYEONG,WON MI SUN,KIM HWAN MOOK,PARK SONG KYU,LEE KIHO,LEE KI HOON,LEE CHANG WOO,LEE JUNG JOON,CHUNG KYUNG SOOK,KIM BO KYUNG,JIN YINGLAN,LEE SEUNG-HEE
- Current Assignee: KOREA RES INST OF BIOSCIENCE,UNIV DONGGUK IND ACAD COOP,LEE KYEONG,WON MI SUN,KIM HWAN MOOK,PARK SONG KYU,LEE KIHO,LEE KI HOON,LEE CHANG WOO,LEE JUNG JOON,CHUNG KYUNG SOOK,KIM BO KYUNG,JIN YINGLAN,LEE SEUNG-HEE
- Priority: KR20100102661 2010-10-20
- Main IPC: C07C235/38
- IPC: C07C235/38 ; A61K31/167 ; A61P35/00 ; C07C231/02
Abstract:
The present invention relates to a compound having HIF-1 inhibition activity, to a method for preparing same, and to a pharmaceutical composition containing same as an active ingredient. The compound of the present invention exhibits anticancer activity by inhibiting the activity of HIF-1, which is a transcription factor that plays a significant role in cancer cell growth and metastasis, and does not indicate non-selective, cytotoxic anti-tumour activity. Accordingly, the compound or a pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumours such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.
Information query
